- Home
- FDMT vs NPCE Comparison
FDMT vs NPCE Comparison
Compare FDMT & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FDMT | NPCE |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.8M | 328.8M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FDMT | NPCE |
|---|---|---|
| Price | $10.99 | $16.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $30.33 | $17.29 |
| AVG Volume (30 Days) | ★ 767.4K | 248.7K |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $120,000.00 | ★ $94,864,000.00 |
| Revenue This Year | $21,181.08 | $24.82 |
| Revenue Next Year | $162.43 | $1.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 605.88 | 24.08 |
| 52 Week Low | $2.24 | $7.56 |
| 52 Week High | $12.34 | $18.98 |
Technical Indicators
Market Signals| Indicator | FDMT | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 53.25 | 62.47 |
| Support Level | $10.30 | $16.00 |
| Resistance Level | $11.50 | $16.94 |
| Average True Range (ATR) | 0.70 | 0.80 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 56.85 | 68.23 |
Price Performance
Historical ComparisonAbout FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.